Abstract 930P
Background
Nodal involvement significantly influences prognostic outcomes in oral squamous cell carcinoma (OSCC). Current staging systems classify pathological extranodal extension (pENE) as N2a and N3b. This study assesses the prognostic efficacy of redefining nodal stages based on quantitative lymph node involvement.
Methods
A single centre retrospective analysis of 3864 patients with oral cancer from 2015 to 2023 was evaluated, and 825 patients with (pENE) OSCC patients were found. The final study analysis included 640 patients examining clinical and pathological variables influencing the DFS and OS. The primary outcome measures were disease-free survival (DFS) and overall survival (OS), analyzed through Cox regression and Kaplan-Meier survival curves.
Results
Of 640 patients, 79.4% were males with a median age of 48. 50% of patients had primary lesions in the buccal mucosa, and 46% had lesions on the tongue and floor of the mouth. Patients with ≤ 4 positive lymph nodes exhibited significantly better DFS (HR 0.53, 95% CI 0.4-0.6, p<0.001) and OS (HR 0.6, 95% CI 0.58-0.79, p<0.001) compared to those with four or more nodes. The mean DFS for patients with ≤ four nodes was 41.4 months, vs 20.5 months in the >4 group. Similarly, the mean OS was 62.3 months in the ≤ lymph node group versus 26.4 months in the >4 group. Multivariate analysis confirmed lymph node count as a robust predictor of survival, outperforming traditional ENE-based classification.
Conclusions
Extranodal extension is a bad prognostic factor in OSCC; however, the number of positive lymph nodes in patients with extranodal extension showed a significant difference in DFS and OS. A further classification in patients with ENE based on positive lymph nodes can give better prognostication; hence, it should be considered to refine the pathological nodal staging system for better prognostication.
Clinical trial identification
Editorial acknowledgement
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1004P - Phase I/II trial of ASP1570, a novel diacylglycerol kinase ζ inhibitor, in patients with advanced solid tumors
Presenter: Daniel Olson
Session: Poster session 03
1005P - Microbial ecosystem therapeutics 4 (MET4) treatment mediates a humoral response in patients treated with immune checkpoint inhibition (ICI)
Presenter: Pavlina Spiliopoulou
Session: Poster session 03
1007P - Systemic STING agonist BI 1703880 plus ezabenlimab in patients (pts) with advanced solid tumors: Initial results from a phase Ia study
Presenter: Kevin Harrington
Session: Poster session 03
1008P - Preliminary clinical PK and PD analysis of a phase I study of ZL-1218, a humanized anti-CCR8 IgG1 antibody, in patients with advanced solid tumors
Presenter: Ignacio Gil Bazo
Session: Poster session 03
1010P - Phase I dose-escalation study of HBM1020: A novel anti-B7H7 antibody in patients with advanced solid tumors
Presenter: Jason Henry
Session: Poster session 03
1011P - Model-informed dose optimization of HFB200301, a TNFR2 agonist monoclonal antibody (mAb), in monotherapy and in combination with the anti-PD-1 mAb tislelizumab (TIS), in patients (pts) with advanced solid tumors
Presenter: Desamparados Roda Perez
Session: Poster session 03
1012P - Safety, tolerability, and efficacy of nadunolimab in combination with pembrolizumab in patients with solid tumors
Presenter: roger cohen
Session: Poster session 03
1013P - A phase I study of rivoceranib combined with nivolumab in patients with unresectable or metastatic cancer
Presenter: Neal Chawla
Session: Poster session 03
1014P - Phase Ib trial results of safety, pharmacokinetics and pharmacodynamics of TU2218, TGFβ-RI and VEGF-R2 dual inhibitor in combination with pembrolizumab in patients with advanced solid tumors
Presenter: Anthony Tolcher
Session: Poster session 03